A cardiac safety study of Secnidazole in healthy individuals at therapeutic and supratherapeutic doses.

Trial Profile

A cardiac safety study of Secnidazole in healthy individuals at therapeutic and supratherapeutic doses.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Secnidazole (Primary) ; Moxifloxacin
  • Indications Bacterial vaginosis
  • Focus Adverse reactions
  • Sponsors Symbiomix Therapeutics
  • Most Recent Events

    • 05 Oct 2017 New trial record
    • 02 Oct 2017 Results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top